The earnings call highlighted Xeris Biopharma's strong financial performance with record revenue growth and successful product performance, particularly for RECORLEV. However, there are increased expenses and potential competitive challenges on the horizon. Despite these concerns, the company's positive financial milestones and strategic growth plans suggest an optimistic outlook.

Company Guidance

During the Xeris Biopharma Q3 2025 earnings call, the company provided robust guidance, highlighting a record-setting quarter with total product revenue exceeding $74 million, marking a 40% year-over-year increase. The company raised the lower end of its full-year total revenue guidance to between $285 million and $290 million, reflecting a 42% increase at the midpoint compared to 2024. Key metrics driving this growth included a 109% increase in RECORLEV revenue, reaching $37 million, and a 108% rise in the average number of patients on RECORLEV therapy. Gvoke's revenue was over $25 million, up nearly 10% year-over-year, while KEVEYIS generated approximately $12 million, driven by new patient additions. Additionally, the company reported improving gross margins at 85%, significant positive cash flow, and net income for the first time. Looking forward, Xeris plans strategic investments in its RECORLEV commercial organization and the development of XP-8121, aiming to maintain positive adjusted EBITDA amidst a continued focus on scalable growth.

Record-Breaking Revenue Growth

Total product revenue exceeded $74 million, representing a 40% increase year-over-year. The full year total revenue guidance was raised to be in the range of $285 million to $290 million, a 42% increase at the midpoint.

RECORLEV Performance

RECORLEV remained the primary growth engine with revenue of $37 million in the quarter, a year-over-year increase of 109%. The average number of patients on therapy grew by 108% versus the same period last year.

Gvoke and KEVEYIS Performance

Gvoke delivered a solid quarter with revenue of more than $25 million, up nearly 10% from the same period last year. KEVEYIS revenue was approximately $12 million, driven by growth in the average number of patients on therapy.

Financial Milestones

The company generated significant positive cash flow and net income for the first time in its history. Adjusted EBITDA for the quarter was $17.4 million, improving more than $20 million compared to Q3 2024.

Xeris Pharmaceuticals (XERS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XERS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 11, 2026	2025 (Q4)	0.03 / -	-0.03	―	―	―
Nov 06, 2025	2025 (Q3)	<0.01 / 0.00	-0.11	―	―
Aug 07, 2025	2025 (Q2)	-0.03 / -0.01	-0.1	90.00% (+0.09)	―
May 08, 2025	2025 (Q1)	-0.05 / -0.06	-0.14	57.14% (+0.08)	―
Mar 06, 2025	2024 (Q4)	-0.06 / -0.03	-0.1	70.00% (+0.07)	―
Nov 08, 2024	2024 (Q3)	-0.09 / -0.11	-0.09	-22.22% (-0.02)	―
Aug 08, 2024	2024 (Q2)	-0.10 / -0.10	-0.14	28.57% (+0.04)	―
May 09, 2024	2024 (Q1)	-0.11 / -0.14	-0.12	-16.67% (-0.02)	―
Mar 06, 2024	2023 (Q4)	-0.09 / -0.10	-0.1	0.00% (0.00)	―
Nov 09, 2023	2023 (Q3)	-0.10 / -0.09	-0.16	43.75% (+0.07)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XERS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	$9.87	$7.71	-21.88%
Aug 07, 2025	$5.49	$6.60	+20.22%
May 08, 2025	$4.48	$5.16	+15.18%
Mar 06, 2025	$3.77	$4.13	+9.55%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Xeris Pharmaceuticals (XERS) report earnings?

Xeris Pharmaceuticals (XERS) is schdueled to report earning on Mar 11, 2026, Before Open (Confirmed).

What is Xeris Pharmaceuticals (XERS) earnings time?

Xeris Pharmaceuticals (XERS) earnings time is at Mar 11, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XERS EPS forecast?

XERS EPS forecast for the fiscal quarter 2025 (Q4) is 0.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing